
Glaukos (GKOS) Stock Forecast & Price Target
Glaukos (GKOS) Analyst Ratings
Bulls say
Glaukos Corporation has demonstrated significant revenue growth in its glaucoma segment, reporting third-quarter revenues of $110 million, exceeding consensus estimates and reflecting a robust 45% increase from the previous quarter. The company's operating margin has notably improved to (7.0%), representing a substantial year-over-year increase of 1,210 basis points and surpassing analyst expectations. Additionally, Glaukos's Corneal Health segment has maintained a strong compound annual growth rate of approximately 15.2% worldwide since 2020, indicating positive momentum and future growth potential for its innovative therapies.
Bears say
Glaukos Corp is experiencing challenges that have resulted in a negative outlook for its stock, primarily due to depressed sales and lower growth rates in its Corneal Health segment, which has seen a compounded annual growth rate (CAGR) decline to approximately 8.9% worldwide over the past three years. The company faces additional risks from slower adoption of its innovative products, such as the iDose and iStent infinite, as well as increasing competition from emerging market entrants that could hinder overall market growth. Furthermore, anticipated declines in revenues from its Legacy Surgical Glaucoma segment, alongside potential changes in reimbursement policies and delayed product launches, contribute to an uncertain financial trajectory for Glaukos.
This aggregate rating is based on analysts' research of Glaukos and is not a guaranteed prediction by Public.com or investment advice.
Glaukos (GKOS) Analyst Forecast & Price Prediction
Start investing in Glaukos (GKOS)
Order type
Buy in
Order amount
Est. shares
0 shares